1. Home
  2. PYPD vs IAF Comparison

PYPD vs IAF Comparison

Compare PYPD & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

N/A

Current Price

$6.55

Market Cap

107.0M

Sector

Health Care

ML Signal

N/A

Logo abrdn Australia Equity Fund Inc.

IAF

abrdn Australia Equity Fund Inc.

N/A

Current Price

$11.49

Market Cap

111.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PYPD
IAF
Founded
2008
1985
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
107.0M
111.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
PYPD
IAF
Price
$6.55
$11.49
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
★ $11.50
N/A
AVG Volume (30 Days)
★ 193.8K
36.3K
Earning Date
11-11-2026
01-01-0001
Dividend Yield
N/A
★ 11.44%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.50
$11.63
52 Week High
$7.15
$14.54

Technical Indicators

Market Signals
Indicator
PYPD
IAF
Relative Strength Index (RSI) 66.97 26.97
Support Level $4.26 N/A
Resistance Level $7.15 $12.84
Average True Range (ATR) 0.52 0.23
MACD 0.05 -0.10
Stochastic Oscillator 64.65 3.08

Price Performance

Historical Comparison
PYPD
IAF

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

About IAF abrdn Australia Equity Fund Inc.

Abrdn Australia Equity Fund Inc is a non-diversified closed-end management investment company. The Fund's principal investment objective is long-term capital appreciation through investment in equity securities of Australian companies listed on the Australian Stock Exchange Limited (ASX). Its secondary objective is current income, which is expected to be derived from dividends and interest on Australian corporate and governmental securities.

Share on Social Networks: